Impact of COVID-19 on patients with atopic dermatitis

Data on the tolerability and response to biologic therapies for type 2 immune disorders in the context of coronavirus disease 2019 (COVID-19) are currently lacking. Our survey aimed at assessing the adherence of patients to dupilumab therapy and the risk of the severe acute respiratory syndrome coro...

Descripción completa

Detalles Bibliográficos
Autores principales: Grieco, Teresa, Chello, Camilla, Sernicola, Alvise, Muharremi, Rovena, Michelini, Simone, Paolino, Giovanni, Carnicelli, Giorgia, Pigatto, Paolo Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
COVID-19: Important updates and developments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285243/
https://www.ncbi.nlm.nih.gov/pubmed/34920828
http://dx.doi.org/10.1016/j.clindermatol.2021.07.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285243/
https://www.ncbi.nlm.nih.gov/pubmed/34920828
http://dx.doi.org/10.1016/j.clindermatol.2021.07.008

Ejemplares similares